CHLOROQUINE PHOSPHATE Drug Patent Profile
✉ Email this page to a colleague
When do Chloroquine Phosphate patents expire, and when can generic versions of Chloroquine Phosphate launch?
Chloroquine Phosphate is a drug marketed by Hikma Pharms, Impax Labs, Ipca Labs Ltd, Md Pharm, Natco Pharma Ltd, Purepac Pharm, Suven Pharms, Teva, and Watson Labs. and is included in thirteen NDAs.
The generic ingredient in CHLOROQUINE PHOSPHATE is chloroquine phosphate. There are twenty drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the chloroquine phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chloroquine Phosphate
A generic version of CHLOROQUINE PHOSPHATE was approved as chloroquine phosphate by IMPAX LABS on August 29th, 2003.
Summary for CHLOROQUINE PHOSPHATE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 13 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 48 |
Patent Applications: | 1,242 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CHLOROQUINE PHOSPHATE at DailyMed |
Recent Clinical Trials for CHLOROQUINE PHOSPHATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Francisco | Phase 2/Phase 3 |
Pan American Health Organization | Phase 2/Phase 3 |
Waterbury Hospital | Phase 3 |
Pharmacology for CHLOROQUINE PHOSPHATE
Drug Class | Antimalarial |